查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1406817

mRNA 治療合約開發和製造市場 - 2018-2028 年全球行業規模、佔有率、趨勢、機會和預測，按應用、按適應症、按最終用戶、按地區和競爭細分

mRNA Therapeutics Contract Development & Manufacturing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Application, By Indication, By End user, By Region and Competition
出版日期: | 出版商: TechSci Research | 英文 183 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2022 年，全球 mRNA 治療合約開發和製造 (CDMO) 市場價值為 85.1 億美元，預計在預測期內將出現令人印象深刻的成長，到 2028 年複合CAGR為7.11%。近年來，醫學領域取得了重大進步，而最具革命性的突破之一是mRNA療法的發展。這些尖端療法利用了信使 RNA (mRNA) 的力量，有潛力解決從癌症到傳染病等多種疾病。隨著這一領域的不斷發展，對專門從事 mRNA 療法的合約開發和製造組織 (CDMO) 的需求也在不斷成長。

信使 RNA (mRNA) 療法代表了一種透過指示人類自身細胞產生治療性蛋白質來治療疾病的新方法。隨著 Pfizer-BioNTech 和 Moderna 等公司開發並成功部署基於 mRNA 的疫苗，這項技術一直是對抗 COVID-19 大流行的最前線。除了疫苗之外，mRNA 療法在治療各種遺傳性疾病、罕見疾病甚至某些癌症方面也具有巨大潛力。隨著 mRNA 療法的前景越來越明顯，對專門 CDMO 的需求激增。 CDMO 在基於 mRNA 的藥物的開發和製造中發揮關鍵作用，提供配方、生產、品質控制和監管合規方面的專業知識。這個細分市場正在迅速擴大，以滿足製藥和生物技術公司不斷成長的需求，這些公司包括老牌企業和新創公司，它們正在大力投資基於 mRNA 的療法。

主要市場促進因素

市場概況
預測期 2024-2028
2022 年市場規模 85.1億美元
2028 年市場規模 128.1億美元
2023-2028 年CAGR 7.11%
成長最快的細分市場 生技與製藥公司
最大的市場 北美洲

研究和開發投資不斷成長正在推動全球 mRNA 治療合約開發和製造 (CDMO) 市場

競爭格局

mRNA治療市場的快速成長吸引了許多參與者，加劇了CDMO之間的競爭。規模較小的 CDMO 可能難以與擁有更多資源和專業知識的規模更大、更成熟的公司競爭。差異化服務以及建立品質和可靠性聲譽對於在這個競爭激烈的行業中取得成功至關重要。

技術創新

mRNA 治療領域不斷發展，新發現和技術快速湧現。 CDMO 必須投資於研發，以維持創新的前沿。隨時了解最新進展至關重要，因為過時的技術可能很快就會過時，從而影響 CDMO 的競爭力。

主要市場趨勢

技術進步

醫學和製藥領域不斷發展，近年來最令人興奮的進步之一是 mRNA 療法的發展。這些突破性的療法在治療從癌症到傳染病等各種疾病方面顯示出巨大的潛力。隨著對 mRNA 療法的需求不斷成長，對專門從事該領域的合約開發和製造組織 (CDMO) 的需求也在不斷成長。

mRNA 療法技術進步的快速擴張一直是 CDMO 市場成長的驅動力。 mRNA 生產方法變得更有效率且可擴展。脂質奈米顆粒 (LNP) 和微流控技術的不斷創新顯著增強了 mRNA 分子的配方和封裝，從而可以開發更穩定、更有效的療法。定序和基因編輯技術的進步促進了個人化 mRNA 療法的發展。 CDMO 現在更有能力為個別患者量身定做 mRNA 治療，為精準醫療開闢了新的可能性。 CDMO 對其製造流程進行了微調，以提高產量並降低生產成本。這使得 mRNA 療法在更廣泛的醫療條件下更容易獲得且經濟可行。製藥公司、研究機構和 CDMO 之間的合作加速了 mRNA 療法的開發。這些合作夥伴關係匯集了 mRNA 技術、藥物開發和製造的專業知識。

細分市場洞察

應用洞察

根據應用類別，病毒疫苗將在 2022 年成為全球 mRNA 治療合約開發和製造 (CDMO) 市場的主導者。病毒疫苗在 mRNA 治療 CDMO 市場中的主導地位對公共健康來說是個好兆頭，因為它有望快速開發新興傳染病的疫苗，並有望在癌症免疫治療方面取得突破。它還強調了 CDMO 在將 mRNA 技術轉化為有形治療方法、最終造福全世界患者方面發揮的關鍵作用。美國 FDA 等監管機構已經認知到 mRNA 技術的潛力，並正在簡化基於 mRNA 的疫苗和治療藥物的核准流程。這種支持鼓勵了該領域的進一步開發和製造。製藥巨頭和生技新創公司都在基於 mRNA 的療法上投入大量投資。針對各種疾病和病症開發 mRNA 疫苗的競賽為專門從事病毒疫苗生產的 CDMO 創造了一個蓬勃發展的市場。基於 mRNA 的癌症疫苗和免疫療法在生物製藥行業中勢頭強勁。這些療法利用人體的免疫系統專門針對癌細胞。隨著該領域研究的進展，CDMO 擴大參與針對個別患者量身定做的個人化癌症疫苗的生產。除了 COVID-19 之外，mRNA 疫苗在解決其他傳染病方面也顯示出前景。 CDMO 在開發流感、寨卡病毒和其他病原體的 mRNA 疫苗方面發揮著至關重要的作用。 mRNA 技術的多功能性使其能夠快速適應新的病毒株，使其成為疫苗開發的一個有吸引力的選擇。

最終使用者見解

生物技術和製藥公司部門預計在預測期內將經歷快速成長。生物技術和製藥公司處於 mRNA 治療研究和開發的前沿。他們投入大量資金來確定新的治療標靶、設計 mRNA 序列並進行臨床前研究以評估這些療法的安全性和有效性。這些公司擁有啟動和管理大規模臨床試驗的資源和基礎設施，這對於獲得監管部門的批准至關重要。 mRNA 療法在治療各種疾病方面顯示出巨大的前景，製藥巨頭熱衷於利用這一潛力。生物技術和製藥公司已經與醫療保健提供者建立了分銷網路和關係，這使得他們在獲得監管部門批准後更容易將 mRNA 療法推向市場。這種管道對於確保這些創新療法惠及有需要的患者至關重要。雖然 CDMO 專注於製造，但生物技術和製藥公司通常擁有自己的製造設施或與 CDMO 建立策略合作夥伴關係。當有前景的 mRNA 療法透過臨床試驗取得進展時，這使他們能夠快速擴大生產規模。

區域洞察

到2022年，北美將成為全球mRNA治療合約開發和製造（CDMO）市場的主導者，以價值計算，佔據最大的市場佔有率。北美在 mRNA 治療 CDMO 市場佔據主導地位的主要原因之一是其蓬勃發展的生物技術生態系統。該地區擁有豐富的生物技術公司、學術機構、研究中心和新創公司網路。這些實體合作推進 mRNA 技術、開發創新療法並提供全面的 CDMO 服務。波士頓、舊金山和聖地牙哥等主要城市已成為全球生物技術創新中心，擁有許多處於 mRNA 研究和開發前沿的公司。世界一流的人才、研究基礎設施和資本投資的存在使北美能夠突破 mRNA 療法的界限。北美領先地位的另一個關鍵因素是強而有力的政府支持和監管框架。美國食品藥物管理局 (FDA) 等政府機構透過簡化監管流程、加快核准速度以及提供研發資金，為 mRNA 療法鋪平了道路。為了因應COVID-19大流行，美國的Operation Warp Speed加速了mRNA疫苗的研發與製造。這項舉措展示了 mRNA 技術的敏捷性和潛力，並進一步鞏固了北美作為該領域領導者的地位。

目錄

第 1 章：產品概述

  • 市場定義
  • 市場範圍
    • 涵蓋的市場
    • 研究年份
    • 主要市場區隔

第 2 章：研究方法

  • 研究目的
  • 基線方法
  • 主要產業夥伴
  • 主要協會和二手資料來源
  • 預測方法
  • 數據三角測量與驗證
  • 假設和限制

第 3 章：執行摘要

  • 市場概況
  • 主要市場細分概述
  • 主要市場參與者概述
  • 重點地區/國家概況
  • 市場促進因素、挑戰、趨勢概述

第 4 章：客戶之聲

第 5 章：全球 mRNA 治療合約開發與製造 (CDMO) 市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按應用（病毒疫苗、蛋白質替代療法、癌症免疫療法）
    • 依適應症（傳染病、代謝及遺傳性疾病、心腦血管疾病）
    • 按最終用戶（生物技術和製藥公司、學術和研究機構、其他）
    • 按地區
    • 按公司分類 (2022)
  • 市場地圖
    • 按應用
    • 按指示
    • 按最終用戶
    • 按地區

第 6 章：北美 mRNA 治療合約開發與製造 (CDMO) 市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按應用
    • 按指示
    • 按最終用戶
    • 按國家/地區

第 7 章：歐洲 mRNA 治療合約開發與製造 (CDMO) 市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按應用
    • 按指示
    • 按最終用戶
    • 按國家/地區

第 8 章：亞太地區 mRNA 治療合約開發與製造 (CDMO) 市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按應用
    • 按指示
    • 按最終用戶
    • 按國家/地區

第 9 章：南美洲 mRNA 治療合約開發與製造 (CDMO) 市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按應用
    • 按指示
    • 按最終用戶
    • 按國家/地區

第 10 章：中東和非洲 mRNA 治療合約開發與製造 (CDMO) 市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按應用
    • 按指示
    • 按最終用戶
    • 按國家/地區

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

  • 近期發展
  • 併購
  • 技術發布

第13章：競爭格局

  • 丹納赫公司（Aldevron）
    • Business Overview
    • Patient Offerings
    • Recent Developments
    • Key Personnel
    • SWOT Analysis
  • 瑞普法姆公司
  • 拜奧邁公司
  • 三星生物製劑
  • 龍沙集團公司
  • 康泰倫特公司
  • 生物指示公司
  • 鐘化歐羅根泰克公司
  • 三聯生技公司
  • 生技公司

第 14 章：策略建議

第 15 章：關於我們與免責聲明

簡介目錄
Product Code: 19805

Global mRNA Therapeutics Contract Development & Manufacturing (CDMO) Market has valued at USD 8.51 Billion in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 7.11% through 2028. The realm of medicine has witnessed significant advancements in recent years, and one of the most revolutionary breakthroughs is the development of mRNA therapeutics. These cutting-edge treatments, which leverage the power of messenger RNA (mRNA), have the potential to tackle a wide range of diseases, from cancer to infectious diseases. As this field continues to grow, so does the demand for contract development and manufacturing organizations (CDMOs) specializing in mRNA therapeutics.

Messenger RNA (mRNA) therapeutics represent a novel approach to treating diseases by instructing the body's own cells to produce therapeutic proteins. This technology has been at the forefront of the fight against the COVID-19 pandemic, with the development and successful deployment of mRNA-based vaccines by companies like Pfizer-BioNTech and Moderna. Beyond vaccines, mRNA therapeutics hold immense potential in the treatment of various genetic disorders, rare diseases, and even certain cancers. As the promise of mRNA therapeutics becomes increasingly evident, the demand for specialized CDMOs has surged. CDMOs play a pivotal role in the development and manufacturing of mRNA-based drugs, offering expertise in formulation, production, quality control, and regulatory compliance. This market segment is expanding rapidly to meet the growing needs of pharmaceutical and biotechnology companies, both established players and startups, who are investing heavily in mRNA-based therapies.

Key Market Drivers

Market Overview
Forecast Period2024-2028
Market Size 2022USD 8.51 Billion
Market Size 2028USD 12.81 Billion
CAGR 2023-20287.11%
Fastest Growing SegmentBiotechnology & Pharmaceutical Companies
Largest MarketNorth America

Growing Investment in Research and Development is Driving the Global mRNA Therapeutics Contract Development & Manufacturing (CDMO) Market

The surge in investment in R&D within the mRNA therapeutics sector has been a driving force behind the growth of the mRNA CDMO market. Several factors contribute to this increased investment. The remarkable success of mRNA-based COVID-19 vaccines has bolstered investor confidence in the technology. This has led to substantial funding for companies engaged in mRNA research and development. The mRNA therapeutics pipeline has expanded rapidly, with candidates in various stages of development for a wide range of diseases. Investors see the potential for mRNA to transform the treatment landscape across multiple therapeutic areas, spurring greater investment. Biopharmaceutical companies are forming partnerships and collaborations with CDMOs to accelerate the development and manufacturing of mRNA therapies. These partnerships often come with substantial financial commitments. Governments worldwide recognize the importance of mRNA therapeutics in addressing public health challenges. As a result, they are allocating significant funding to support research and development efforts in this field.

Expanding Therapeutic Applications is Driving the Global mRNA Therapeutics Contract Development & Manufacturing (CDMO) Market

One of the primary factors propelling the mRNA therapeutics CDMO market's growth is the increasing number of therapeutic applications. Initially, mRNA technology gained prominence for its potential in developing vaccines, as seen in the rapid development of COVID-19 vaccines by Pfizer-BioNTech and Moderna. However, its utility extends far beyond vaccines.

mRNA therapeutics are being explored for cancer treatment, with the ability to trigger an immune response against cancer cells or directly target them with specific therapies. mRNA can be used to correct genetic mutations responsible for rare diseases, offering hope to patients who previously had limited treatment options. mRNA technology can be adapted to create vaccines and treatments for various infectious diseases, from influenza to HIV. mRNA can be harnessed to modulate the immune system's response and treat autoimmune conditions like multiple sclerosis and rheumatoid arthritis. Researchers are investigating mRNA therapies to combat heart diseases by targeting specific genes associated with these conditions. mRNA therapeutics hold promise in treating neurological disorders, including Alzheimer's and Parkinson's disease.

As research continues to uncover new therapeutic opportunities, the demand for mRNA therapeutics CDMOs is expected to surge, as these organizations play a pivotal role in translating research into market-ready therapies. Contract development and manufacturing organizations specializing in mRNA therapeutics are crucial to the industry's success. These CDMOs provide essential services to biopharmaceutical companies, startups, and research institutions, allowing them to leverage mRNA technology without building their own production capabilities from scratch.

CDMOs can synthesize mRNA molecules tailored to specific therapeutic targets, ensuring precise and effective treatments. They optimize mRNA production processes, improving efficiency, scalability, and cost-effectiveness. CDMOs have the infrastructure and expertise to manufacture mRNA therapeutics at scale, meeting the growing demand. Ensuring that mRNA therapies meet rigorous quality and regulatory standards is vital, and CDMOs excel in this area. CDMOs expedite the development and production of mRNA therapeutics, allowing treatments to reach patients faster.

Key Market Challenges

Regulatory Hurdles

One of the most significant challenges in the mRNA therapeutics CDMO market is navigating complex regulatory landscapes. mRNA-based therapies represent a new frontier in medicine, and regulatory agencies worldwide are continually updating and adapting their guidelines. Manufacturers must ensure that their production processes and facilities meet stringent regulatory standards, which can vary from one region to another. Achieving regulatory compliance is a resource-intensive and time-consuming task that can delay product development and market entry.

Scalability Issues

Scalability is another major challenge faced by CDMOs in the mRNA therapeutics market. The production of mRNA vaccines and therapies requires state-of-the-art manufacturing facilities and equipment. Scaling up production capacity quickly to meet high demand, as seen during the COVID-19 pandemic, can be a logistical nightmare. Furthermore, mRNA therapies often involve complex and delicate processes that must be carefully controlled to maintain product quality and efficacy during scale-up.

Supply Chain Vulnerabilities

The global supply chain is vulnerable to various disruptions, including geopolitical tensions, natural disasters, and unexpected events like the COVID-19 pandemic. These disruptions can lead to shortages of critical raw materials, equipment, and skilled personnel needed for mRNA production. CDMOs must develop resilient supply chains, diversify sourcing options, and establish contingency plans to mitigate these risks.

Intellectual Property and Licensing

The mRNA therapeutics market is characterized by a complex web of intellectual property rights and licensing agreements. Many key technologies and patents are held by different companies and institutions, making it challenging for CDMOs to navigate the landscape. Negotiating licensing agreements, royalty payments, and compliance with various patents can add significant complexity and costs to mRNA therapy development.

Cost and Pricing Pressures

Developing and manufacturing mRNA therapies can be costly, especially in the early stages when technologies are still being optimized. Pricing pressures, both from healthcare systems and patient advocacy groups, can limit the profitability of mRNA CDMOs. Balancing the need for affordable treatments with the costs of research, development, and manufacturing poses a constant challenge.

Competitive Landscape

The rapid growth of the mRNA therapeutics market has attracted numerous players, increasing competition among CDMOs. Smaller CDMOs may struggle to compete with larger, more established firms that have greater resources and expertise. Differentiating services and establishing a reputation for quality and reliability are vital for success in this highly competitive industry.

Technological Innovation

The mRNA therapeutics field is continuously evolving, with new discoveries and technologies emerging at a rapid pace. CDMOs must invest in research and development to stay at the forefront of innovation. Staying updated with the latest advancements is crucial, as outdated technologies can quickly become obsolete, impacting the competitiveness of a CDMO.

Key Market Trends

Technological Advancements

The field of medicine and pharmaceuticals is constantly evolving, and one of the most exciting advancements in recent years has been the development of mRNA therapeutics. These groundbreaking therapies have shown immense potential in treating various diseases, from cancer to infectious diseases. As the demand for mRNA therapeutics continues to grow, so does the need for contract development and manufacturing organizations (CDMOs) specialized in this field.

The rapid expansion of technological advancements in mRNA therapeutics has been a driving force behind the growth of the CDMO market. mRNA production methods have become more efficient and scalable. Continuous innovations in lipid nanoparticles (LNPs) and microfluidic technologies have significantly enhanced the formulation and encapsulation of mRNA molecules, allowing for the development of more stable and effective therapies. Advancements in sequencing and gene editing technologies have enabled the development of personalized mRNA therapies. CDMOs are now better equipped to tailor mRNA treatments to individual patients, opening up new possibilities in precision medicine. CDMOs have fine-tuned their manufacturing processes to increase yields and reduce production costs. This has made mRNA therapies more accessible and economically viable for a broader range of medical conditions. Collaboration between pharmaceutical companies, research institutions, and CDMOs has accelerated the development of mRNA therapies. These partnerships bring together expertise in mRNA technology, drug development, and manufacturing.

Segmental Insights

Application Insights

Based on the category of Application, Viral Vaccines emerged as the dominant player in the global market for mRNA Therapeutics Contract Development & Manufacturing (CDMO) in 2022. The dominance of viral vaccines in the mRNA Therapeutics CDMO market bodes well for public health, as it promises the rapid development of vaccines for emerging infectious diseases and the potential for breakthroughs in cancer immunotherapy. It also highlights the critical role CDMOs play in translating mRNA technology into tangible treatments, ultimately benefiting patients worldwide. Regulatory agencies such as the U.S. FDA have recognized the potential of mRNA technology and are streamlining the approval process for mRNA-based vaccines and therapeutics. This support encourages further development and manufacturing in this space. Pharmaceutical giants and biotech startups alike are pouring substantial investments into mRNA-based therapies. The race to develop mRNA vaccines for various diseases and conditions has created a booming market for CDMOs specializing in viral vaccine production. mRNA-based cancer vaccines and immunotherapies are gaining momentum in the biopharmaceutical industry. These therapies leverage the body's immune system to target cancer cells specifically. As research in this field advances, CDMOs are increasingly involved in the manufacturing of personalized cancer vaccines tailored to individual patients. Beyond COVID-19, mRNA vaccines have demonstrated promise in addressing other infectious diseases. CDMOs are playing a vital role in developing mRNA vaccines for influenza, Zika virus, and other pathogens. The versatility of mRNA technology allows for rapid adaptation to new viral strains, making it an attractive option for vaccine development.

End User Insights

The Biotechnology & Pharmaceutical Companies segment is projected to experience rapid growth during the forecast period. Biotechnology and pharmaceutical companies are at the forefront of mRNA therapeutic research and development. They invest heavily in identifying new therapeutic targets, designing mRNA sequences, and conducting pre-clinical studies to evaluate the safety and efficacy of these therapies. These companies have the resources and infrastructure to initiate and manage large-scale clinical trials, which are crucial for gaining regulatory approvals. mRNA therapies have shown immense promise in treating various diseases, and pharmaceutical giants are keen to capitalize on this potential. Biotechnology and pharmaceutical companies have established distribution networks and relationships with healthcare providers, making it easier for them to bring mRNA therapies to market once they receive regulatory approval. This access is crucial for ensuring that these innovative treatments reach patients in need. While CDMOs specialize in manufacturing, biotechnology and pharmaceutical companies often have their own manufacturing facilities or strategic partnerships with CDMOs. This enables them to scale up production quickly when a promising mRNA therapy advances through clinical trials.

Regional Insights

North America emerged as the dominant player in the global mRNA Therapeutics Contract Development & Manufacturing (CDMO) market in 2022, holding the largest market share in terms of value. One of the primary reasons for North America's dominance in the mRNA therapeutics CDMO market is its thriving biotechnology ecosystem. The region boasts a rich network of biotech companies, academic institutions, research centers, and startups. These entities collaborate to advance mRNA technology, develop innovative therapies, and provide comprehensive CDMO services. Key cities like Boston, San Francisco, and San Diego have become global hubs for biotech innovation, housing numerous companies at the forefront of mRNA research and development. The presence of world-class talent, research infrastructure, and capital investment has allowed North America to push the boundaries of mRNA therapeutics. Another pivotal factor in North America's leadership is the strong government support and regulatory framework in place. Government agencies such as the Food and Drug Administration (FDA) in the United States have paved the way for mRNA therapies by streamlining regulatory processes, expediting approvals, and providing funding for research and development. In response to the COVID-19 pandemic, Operation Warp Speed in the United States accelerated the development and manufacturing of mRNA vaccines. This initiative showcased the agility and potential of mRNA technology and further solidified North America's position as a leader in the field.

Key Market Players

Danaher corporation (Aldevron)

Recipharm AB

Biomay AG

Samsung Biologics

Lonza Group AG

Catalent , Inc

Bio-Indication Inc

Kaneka Eurogentec S.A

TriLink BioTechnologies

BioNTech SE

Report Scope:

In this report, the Global mRNA Therapeutics Contract Development & Manufacturing (CDMO) Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

mRNA Therapeutics Contract Development & Manufacturing (CDMO) Market, By Application:

  • Viral Vaccines
  • Protein Replacement Therapies
  • Cancer Immunotherapies

mRNA Therapeutics Contract Development & Manufacturing (CDMO) Market, By Indication:

  • Infectious Diseases
  • Metabolic & Genetic Diseases
  • Cardiovascular & Cerebrovascular Diseases

mRNA Therapeutics Contract Development & Manufacturing (CDMO) Market, By End user:

  • Biotechnology & Pharmaceutical Companies
  • Academic & Research Institutions
  • Others

mRNA Therapeutics Contract Development & Manufacturing (CDMO) Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies presents in the mRNA Therapeutics Contract Development & Manufacturing (CDMO) Market.

Available Customizations:

  • Global mRNA Therapeutics Contract Development & Manufacturing (CDMO) market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Application (Viral Vaccines, Protein Replacement Therapies, Cancer Immunotherapies)
    • 5.2.2. By Indication ( Infectious Diseases, Metabolic & Genetic Diseases, Cardiovascular & Cerebrovascular Diseases)
    • 5.2.3. By End user (Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2022)
  • 5.3. Market Map
    • 5.3.1. By Application
    • 5.3.2. By Indication
    • 5.3.3. By End user
    • 5.3.4. By Region

6. North America mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Application
    • 6.2.2. By Indication
    • 6.2.3. By End user
    • 6.2.4. By Country
      • 6.2.4.1. United States mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Outlook
        • 6.2.4.1.1. Market Size & Forecast
        • 6.2.4.1.1.1. By Value
        • 6.2.4.1.2. Market Share & Forecast
        • 6.2.4.1.2.1. By Application
        • 6.2.4.1.2.2. By Indication
        • 6.2.4.1.2.3. By End user
      • 6.2.4.2. Canada mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Outlook
        • 6.2.4.2.1. Market Size & Forecast
        • 6.2.4.2.1.1. By Value
        • 6.2.4.2.2. Market Share & Forecast
        • 6.2.4.2.2.1. By Application
        • 6.2.4.2.2.2. By Indication
        • 6.2.4.2.2.3. By End user
      • 6.2.4.3. Mexico mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Outlook
        • 6.2.4.3.1. Market Size & Forecast
        • 6.2.4.3.1.1. By Value
        • 6.2.4.3.2. Market Share & Forecast
        • 6.2.4.3.2.1. By Application
        • 6.2.4.3.2.2. By Indication
        • 6.2.4.3.2.3. By End user

7. Europe mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Application
    • 7.2.2. By Indication
    • 7.2.3. By End user
    • 7.2.4. By Country
      • 7.2.4.1. France mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Outlook
        • 7.2.4.1.1. Market Size & Forecast
        • 7.2.4.1.1.1. By Value
        • 7.2.4.1.2. Market Share & Forecast
        • 7.2.4.1.2.1. By Application
        • 7.2.4.1.2.2. By Indication
        • 7.2.4.1.2.3. By End user
      • 7.2.4.2. Germany mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Outlook
        • 7.2.4.2.1. Market Size & Forecast
        • 7.2.4.2.1.1. By Value
        • 7.2.4.2.2. Market Share & Forecast
        • 7.2.4.2.2.1. By Application
        • 7.2.4.2.2.2. By Indication
        • 7.2.4.2.2.3. By End user
      • 7.2.4.3. United Kingdom mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Outlook
        • 7.2.4.3.1. Market Size & Forecast
        • 7.2.4.3.1.1. By Value
        • 7.2.4.3.2. Market Share & Forecast
        • 7.2.4.3.2.1. By Application
        • 7.2.4.3.2.2. By Indication
        • 7.2.4.3.2.3. By End user
      • 7.2.4.4. Italy mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Outlook
        • 7.2.4.4.1. Market Size & Forecast
        • 7.2.4.4.1.1. By Value
        • 7.2.4.4.2. Market Share & Forecast
        • 7.2.4.4.2.1. By Application
        • 7.2.4.4.2.2. By Indication
        • 7.2.4.4.2.3. By End user
      • 7.2.4.5. Spain mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Outlook
        • 7.2.4.5.1. Market Size & Forecast
        • 7.2.4.5.1.1. By Value
        • 7.2.4.5.2. Market Share & Forecast
        • 7.2.4.5.2.1. By Application
        • 7.2.4.5.2.2. By Indication
        • 7.2.4.5.2.3. By End user

8. Asia Pacific mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Application
    • 8.2.2. By Indication
    • 8.2.3. By End user
    • 8.2.4. By Country
      • 8.2.4.1. China mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Outlook
        • 8.2.4.1.1. Market Size & Forecast
        • 8.2.4.1.1.1. By Value
        • 8.2.4.1.2. Market Share & Forecast
        • 8.2.4.1.2.1. By Application
        • 8.2.4.1.2.2. By Indication
        • 8.2.4.1.2.3. By End user
      • 8.2.4.2. India mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Outlook
        • 8.2.4.2.1. Market Size & Forecast
        • 8.2.4.2.1.1. By Value
        • 8.2.4.2.2. Market Share & Forecast
        • 8.2.4.2.2.1. By Application
        • 8.2.4.2.2.2. By Indication
        • 8.2.4.2.2.3. By End user
      • 8.2.4.3. South Korea mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Outlook
        • 8.2.4.3.1. Market Size & Forecast
        • 8.2.4.3.1.1. By Value
        • 8.2.4.3.2. Market Share & Forecast
        • 8.2.4.3.2.1. By Application
        • 8.2.4.3.2.2. By Indication
        • 8.2.4.3.2.3. By End user
      • 8.2.4.4. Japan mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Outlook
        • 8.2.4.4.1. Market Size & Forecast
        • 8.2.4.4.1.1. By Value
        • 8.2.4.4.2. Market Share & Forecast
        • 8.2.4.4.2.1. By Application
        • 8.2.4.4.2.2. By Indication
        • 8.2.4.4.2.3. By End user
      • 8.2.4.5. Australia mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Outlook
        • 8.2.4.5.1. Market Size & Forecast
        • 8.2.4.5.1.1. By Value
        • 8.2.4.5.2. Market Share & Forecast
        • 8.2.4.5.2.1. By Application
        • 8.2.4.5.2.2. By Indication
        • 8.2.4.5.2.3. By End user

9. South America mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Application
    • 9.2.2. By Indication
    • 9.2.3. By End user
    • 9.2.4. By Country
      • 9.2.4.1. Brazil mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Outlook
        • 9.2.4.1.1. Market Size & Forecast
        • 9.2.4.1.1.1. By Value
        • 9.2.4.1.2. Market Share & Forecast
        • 9.2.4.1.2.1. By Application
        • 9.2.4.1.2.2. By Indication
        • 9.2.4.1.2.3. By End user
      • 9.2.4.2. Argentina mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Outlook
        • 9.2.4.2.1. Market Size & Forecast
        • 9.2.4.2.1.1. By Value
        • 9.2.4.2.2. Market Share & Forecast
        • 9.2.4.2.2.1. By Application
        • 9.2.4.2.2.2. By Indication
        • 9.2.4.2.2.3. By End user
      • 9.2.4.3. Colombia mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Outlook
        • 9.2.4.3.1. Market Size & Forecast
        • 9.2.4.3.1.1. By Value
        • 9.2.4.3.2. Market Share & Forecast
        • 9.2.4.3.2.1. By Application
        • 9.2.4.3.2.2. By Indication
        • 9.2.4.3.2.3. By End user

10. Middle East & Africa mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Application
    • 10.2.2. By Indication
    • 10.2.3. By End user
    • 10.2.4. By Country
      • 10.2.4.1. South Africa mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Outlook
        • 10.2.4.1.1. Market Size & Forecast
        • 10.2.4.1.1.1. By Value
        • 10.2.4.1.2. Market Share & Forecast
        • 10.2.4.1.2.1. By Application
        • 10.2.4.1.2.2. By Indication
        • 10.2.4.1.2.3. By End user
      • 10.2.4.2. Saudi Arabia mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Outlook
        • 10.2.4.2.1. Market Size & Forecast
        • 10.2.4.2.1.1. By Value
        • 10.2.4.2.2. Market Share & Forecast
        • 10.2.4.2.2.1. By Application
        • 10.2.4.2.2.2. By Indication
        • 10.2.4.2.2.3. By End user
      • 10.2.4.3. UAE mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Outlook
        • 10.2.4.3.1. Market Size & Forecast
        • 10.2.4.3.1.1. By Value
        • 10.2.4.3.2. Market Share & Forecast
        • 10.2.4.3.2.1. By Application
        • 10.2.4.3.2.2. By Indication
        • 10.2.4.3.2.3. By End user

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Technology Launches

13. Competitive Landscape

  • 13.1. Danaher corporation (Aldevron)
    • 13.1.1. Business Overview
    • 13.1.2. Patient Offerings
    • 13.1.3. Recent Developments
    • 13.1.4. Key Personnel
    • 13.1.5. SWOT Analysis
  • 13.2. Recipharm AB
  • 13.3. Biomay AG
  • 13.4. Samsung Biologics
  • 13.5. Lonza Group AG
  • 13.6. Catalent , Inc
  • 13.7. Bio-Indication Inc
  • 13.8. Kaneka Eurogentec S.A
  • 13.9. TriLink BioTechnologies
  • 13.10. BioNTech SE

14. Strategic Recommendations

15. About us & Disclaimer